Sanofi

Forma Therapeutics Announces Appointment of New Executive Team Members

Retrieved on: 
Thursday, June 30, 2022

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer, and other rare hematologic diseases and cancers, today announced the appointment of Agustn Melin, M.D.

Key Points: 
  • Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer, and other rare hematologic diseases and cancers, today announced the appointment of Agustn Melin, M.D.
  • In this capacity, he led the cross-functional research and development medical staff outside of the U.S. as well as Japan.
  • Forma has a differentiated patient-centric culture and an amazing team.
  • Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers.

Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors

Retrieved on: 
Wednesday, June 29, 2022

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (Ligand or the Company) announces the appointment of Jason Haas to the Company's Board of Directors.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (Ligand or the Company) announces the appointment of Jason Haas to the Company's Board of Directors.
  • Mr. Haas brings more than 30 years of healthcare investment banking and corporate finance experience to Ligand.
  • Jason is a particularly opportune addition as we begin to reformulate the Ligand Board following the upcoming spin-off of OmniAb.
  • We welcome Jason to Ligands Board of Directors with delight and look forward to him adding to his already impressive legacy of benchmark transactions to Ligands business.

Reach3 Insights Launches Health Practice

Retrieved on: 
Wednesday, June 29, 2022

The new Health practice will round out Reach3s industry-specific insight teams, which currently include Technology & Media, CPG, Retail and Financial Services.

Key Points: 
  • The new Health practice will round out Reach3s industry-specific insight teams, which currently include Technology & Media, CPG, Retail and Financial Services.
  • The health industry is one of the biggest consumers of marketing intelligence and includes Pharma/Biotech, Hospital Systems, Health Insurers, Medical Devices and other ancillary health services.
  • With the addition of Palmer and Perkins, this practice will serve the industrys need for applying more innovative methods to uncovering critical business insights.
  • Since launching Reach3 Insights just over 4 years ago, weve been amazed at client demand for our immersive mobile messaging-based insight solutions that enable companies to get closer to the context driving human behaviors, said Founder & CEO of Reach3 Insights, Matt Kleinschmit.

Prescient Announces Recent Appointments to Its Senior Advisory Team and the Opening of Its 10th Location

Retrieved on: 
Wednesday, June 29, 2022

LONDON, June 29, 2022  /PRNewswire/ -- Prescient, a biopharma product and portfolio strategy firm, has announced the recent appointments of Dr. Olga Fidalgo González and Claudio Jouanneau as leaders in its Advisory business. Prescient has also expanded its global footprint with a new office in Barcelona.

Key Points: 
  • LONDON, June 29, 2022 /PRNewswire/ -- Prescient, a biopharma product and portfolio strategy firm, has announced the recent appointments of Dr. Olga Fidalgo Gonzlez and Claudio Jouanneau as leaders in its Advisory business.
  • At Prescient, Olga is responsible for championing the development of the Barcelona-based Advisory team, contributing to growing our European Advisory business and supporting our clients to address their strategic and operational challenges.
  • At Prescient, Claudio is responsible for building our Spanish Advisory team and supporting the growth of our European Advisory business.
  • Prescient has been a portfolio company of Bridgepoint Development Capital since 2021 and Baird Capital since 2017.

Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors

Retrieved on: 
Tuesday, June 28, 2022

We are pleased to continue our work with Dr. Bergstrom and to welcome Mr. Malkomes to the Cellectis Board.

Key Points: 
  • We are pleased to continue our work with Dr. Bergstrom and to welcome Mr. Malkomes to the Cellectis Board.
  • As of today, Dr. Bergstrom will serve as Director of Cellectis Board.
  • Previously, Donald A Bergstrom, M.D., Ph.D., was appointed as a Board Observer on the Companys Board of Directors on November 4, 2021.
  • Dr. Bergstrom currently serves as Executive Vice President, Head of Research and Development at Relay Therapeutics, Inc., a clinical-stage precision medicines company.

Icertis Wins Microsoft 2022 US Partner of the Year Award

Retrieved on: 
Tuesday, June 28, 2022

BELLEVUE, Wash., June 28, 2022 /PRNewswire/ -- Icertis, the contract intelligence company that pushes the boundaries of what's possible with contract lifecycle management (CLM), announced today that it has won the 2022 Microsoft Partner of the Year Award for the United States. The company was honored among a global field of top Microsoft partners for demonstrating excellence in innovation and implementation of customer solutions based on Microsoft technology. The award underscores the significant value that Icertis and Microsoft are delivering to customers, grounded in a decade of collaboration focused on digitally transforming enterprise contracting with cloud and AI technology. Icertis was also named Microsoft US Partner of the Year in 2018.

Key Points: 
  • Icertis was also named Microsoft US Partner of the Year in 2018.
  • Icertis' 2022 Microsoft US Partner of the Year award continues the company's five-year streak of Microsoft Partner of the Year award recognitions including:
    2021 Winner AI Partner of the Year and Finalist Global Independent Software Vendor (ISV) Partner of the Year;
    2020 Finalist Alliance Global ISV Partner of the Year and Finalist Manufacturing Partner of the Year;
    2019 Winner Microsoft US Partner Award for Manufacturing & Resources, Finalist Microsoft US Partner Award for Automotive, and Finalist Global Partner Global ISV and Automotive;
    2018 Winner Microsoft US Partner of the Year, Finalist Platform Partner of the Year, and Finalist Manufacturing Partner of the Year.
  • "I am honored to announce the winners and finalists of the 2022 Microsoft Partner of the Year Awards," said Nick Parker, Corporate Vice President of Global Partner Solutions at Microsoft.
  • Icertis will be honored for its award-winning Icertis Contract Intelligence platform at Microsoft Inspire , held July 19-20, 2022, during the United States Keynote presentation.

Survey: Digital Workplaces Help Frontline Teams Look Beyond the "Big Quit"

Retrieved on: 
Tuesday, June 28, 2022

NEW YORK , June 28, 2022 /PRNewswire/ -- YOOBIC, the digital workplace leader, today announced the publication of the 2022 State of the Frontline Employee Experience survey — a major global report offering unique insights into the challenges facing retail and hospitality workers and their employers in an era of COVID-19, labor shortages, supply chain disruptions, and economic uncertainty.

Key Points: 
  • More than two-thirds of frontline employees feel close to their coworkers, but they want their employers to do more to create connected workplaces and share HQ's leadership vision with frontline teams.
  • But frontline teams are also eager to work with their employers to find positive solutions to the challenges they face.
  • "With digital workplace solutions to drive collaboration, engagement, and learning, employers can reward their frontline teams, boost employee retention and productivity, and help turn hospitality and retail work into lifelong careers of which frontline workers can feel truly proud."
  • With streamlined communications, mobile learning, and digitized task management, YOOBIC drives operational excellence while drastically improving the frontline employee working experience.

G1 Therapeutics Announces Addition of Jacks Lee to Board of Directors

Retrieved on: 
Tuesday, June 28, 2022

RESEARCH TRIANGLE PARK, N.C., June 28, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Jacks Lee to its Board of Directors.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., June 28, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Jacks Lee to its Board of Directors.
  • I am delighted to welcome Jacks to our Board of Directors at this exciting point in our evolution."
  • Few companies in this sector have proven expertise in both drug development and commercial execution; G1 is one of those few, said Mr. Lee.
  • G1 Therapeutics and the G1 Therapeutics logo and COSELA and the COSELA logo are trademarks of G1 Therapeutics, Inc.

Press Release: Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD

Retrieved on: 
Tuesday, June 28, 2022

The European Commission (EC) has approved Xenpozyme (olipudase alfa) as the first and only enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in pediatric and adult patients with ASMD type A/B or ASMD type B.

Key Points: 
  • The European Commission (EC) has approved Xenpozyme (olipudase alfa) as the first and only enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in pediatric and adult patients with ASMD type A/B or ASMD type B.
  • Given the urgent unmet medical needs of the ASMD community, the European Medicines Agency (EMA) granted Xenpozyme PRIority MEdicines (PRIME) designation.
  • We welcome the European Union approval of Xenpozyme as the first and only disease-specific therapy for ASMD with a potential to oppose disease progression.
  • Xenpozyme has been evaluated in pediatric and adult patients to treat non-CNS manifestations of ASMD type A/B and ASMD type B. Xenpozyme has not been studied in patients with ASMD type A.

Sanofi Enters into a Partnering Agreement with Health2Sync

Retrieved on: 
Tuesday, June 28, 2022

TAIPEI and TOKYO, June 27, 2022 /PRNewswire/ -- Sanofi K.K. (Head office: Shinjuku-ku, Tokyo; President: Takahiko Iwaya; hereinafter "Sanofi") and Health2Sync. (Head office: Taito-ku, Tokyo; CEO: Ed Deng) have entered into a partnering agreement to support healthcare professionals and people living with diabetes mellitus through digital support programs.

Key Points: 
  • (Head office: Shinjuku-ku, Tokyo; President: Takahiko Iwaya; hereinafter "Sanofi") and Health2Sync.
  • (Head office: Taito-ku, Tokyo; CEO: Ed Deng) have entered into a partnering agreement to support healthcare professionals and people living with diabetes mellitus through digital support programs.
  • Moving forward, Sanofi and Health2Sync plan to further collaborate in bringing innovative digital therapeutics solutions to patients and healthcare professionals in Japan and other markets.
  • Please visit the website http://www.sanofi.co.jp for details about Sanofi K.K, the Japanese subsidiary of Sanofi.